Literature DB >> 19279328

Evidence for distinct antagonist-revealed functional states of 5-hydroxytryptamine(2A) receptor homodimers.

José Brea1, Marián Castro, Jesús Giraldo, Juan F López-Giménez, Juan Fernando Padín, Fátima Quintián, Maria Isabel Cadavid, Maria Teresa Vilaró, Guadalupe Mengod, Kelly A Berg, William P Clarke, Jean-Pierre Vilardaga, Graeme Milligan, Maria Isabel Loza.   

Abstract

The serotonin (5-hydroxytryptamine; 5-HT) 2A receptor is a cell surface class A G protein-coupled receptor that regulates a multitude of physiological functions of the body and is a target for antipsychotic drugs. Here we found by means of fluorescence resonance energy transfer and immunoprecipitation studies that the 5-HT(2A)-receptor homodimerized in live cells, which we linked with its antagonist-dependent fingerprint in both binding and receptor signaling. Some antagonists, like the atypical antipsychotics clozapine and risperidone, differentiate themselves from others, like the typical antipsychotic haloperidol, antagonizing these 5-HT(2A) receptor-mediated functions in a pathway-specific manner, explained here by a new model of multiple active interconvertible conformations at dimeric receptors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19279328     DOI: 10.1124/mol.108.054395

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  21 in total

Review 1.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 2.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  The prevalence, maintenance, and relevance of G protein-coupled receptor oligomerization.

Authors:  Graeme Milligan
Journal:  Mol Pharmacol       Date:  2013-04-30       Impact factor: 4.436

Review 4.  G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives.

Authors:  Sergi Ferré; Vicent Casadó; Lakshmi A Devi; Marta Filizola; Ralf Jockers; Martin J Lohse; Graeme Milligan; Jean-Philippe Pin; Xavier Guitart
Journal:  Pharmacol Rev       Date:  2014-02-10       Impact factor: 25.468

5.  Delineation of molecular determinants for FR900359 inhibition of Gq/11 unlocks inhibition of Gαs.

Authors:  Michael W Boesgaard; Kasper Harpsøe; Michelle Malmberg; Christina R Underwood; Asuka Inoue; Jesper M Mathiesen; Gabriele M König; Evi Kostenis; David E Gloriam; Hans Bräuner-Osborne
Journal:  J Biol Chem       Date:  2020-08-04       Impact factor: 5.157

6.  Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.

Authors:  Clinton E Canal
Journal:  Handb Exp Pharmacol       Date:  2018

7.  Fluorescence correlation spectroscopy analysis of serotonin, adrenergic, muscarinic, and dopamine receptor dimerization: the oligomer number puzzle.

Authors:  Katharine Herrick-Davis; Ellinor Grinde; Ann Cowan; Joseph E Mazurkiewicz
Journal:  Mol Pharmacol       Date:  2013-08-01       Impact factor: 4.436

8.  Novel Bivalent 5-HT2A Receptor Antagonists Exhibit High Affinity and Potency in Vitro and Efficacy in Vivo.

Authors:  Claudia A Soto; Matthew J Shashack; Robert G Fox; Marcy J Bubar; Kenner C Rice; Cheryl S Watson; Kathryn A Cunningham; Scott R Gilbertson; Noelle C Anastasio
Journal:  ACS Chem Neurosci       Date:  2017-11-21       Impact factor: 4.418

9.  Multiple conformations of 5-HT2A and 5-HT 2C receptors in rat brain: an autoradiographic study with [125I](±)DOI.

Authors:  Juan F López-Giménez; M Teresa Vilaró; José M Palacios; Guadalupe Mengod
Journal:  Exp Brain Res       Date:  2013-07-18       Impact factor: 1.972

Review 10.  Functional significance of serotonin receptor dimerization.

Authors:  Katharine Herrick-Davis
Journal:  Exp Brain Res       Date:  2013-06-29       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.